FLUCONAZOLE


Trade Names	DIFLUCAN DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER DIFLUCAN IN SODIUM CHLORIDE 0.9% DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER FLUCONAZOLE FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER FLUCONAZOLE IN SODIUM CHLORIDE 0.9% FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Synonyms	Alkanazole BAYT-006267 BAYT006267 Canesten oral Diflucan Diflucan In Sodium Chloride Diflucan one Difluconazole Fluconazole Fluconazole In Sodium Chloride Fluconazoli NSC-758661 Triflucan UK-49,858 UK-49858
Status
Molecule Category	Free-form
ATC	D01AC15 J02AC01
UNII	8VZV102JFY
EPA CompTox	DTXSID3020627

Structure


InChI Key	RFHAOTPXVQNOHP-UHFFFAOYSA-N
Smiles	OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
InChI	InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H12F2N6O
Molecular Weight	306.28
AlogP	0.74
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	81.65
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	22.0

Pharmacology

Mechanism of Action	Action	Reference
Cytochrome P450 51 inhibitor	INHIBITOR	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C9	-	-	-	-	89.09-89.09
Enzyme Cytochrome P450 Cytochrome P450 family 51 Cytochrome P450 family 51A Cytochrome P450 51A1	-	116-134	45-200	-	1.92-51.16
Enzyme Oxidoreductase	-	880	230-230	-	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	7.4-106.49
Unclassified protein	-	-	-	-	0-9

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Aspergillus flavus	-	-	-	-	74.6-77.7
Aspergillus niger	-	-	-	-	75.3-81.1
Candida albicans	-	1-980	45-230	-	1.92-100
Candida albicans SC5314	-	116	-	-	-
Cricetulus griseus	-	-	-	-	86.64-106.49
Cryptococcus neoformans	-	5-700	-	-	58.95-64.92
Cryptococcus neoformans var. grubii H99	-	950	-	-	-
Homo sapiens	-	-	-	-	7.4-89.09
Mus musculus	-	-	-	-	5.9
Mycobacterium tuberculosis	-	-	200	-	-
Nannizzia gypsea	-	-	-	-	61.3
Saccharomyces cerevisiae	-	-	-	-	0-9
Trichophyton mentagrophytes	-	-	-	-	61.3
Trypanosoma cruzi	-	880	230-230	-	-

Environmental Exposure

Environmental Exposure Map

Countries
Croatia
Czech Republic
Germany
Hungary
India
Romania
Slovakia
Slovenia
USA

Cross References

Resources	Reference
ChEBI	46081
ChEMBL	CHEMBL106
DrugBank	DB00196
DrugCentral	1187
FDA SRS	8VZV102JFY
Human Metabolome Database	HMDB0014342
KEGG	D00322
PDB	TPF
PharmGKB	PA449653
PubChem	3365
SureChEMBL	SCHEMBL3151
ZINC	ZINC000000004009

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).